Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma.

Trial Profile

A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma; Eosinophilia
  • Focus Registrational; Therapeutic Use
  • Acronyms BREATH
  • Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 18 Aug 2016 According to a Teva Pharmaceuticals media release, based on the data from this and other four trials (700194103, 700194191, 700212125 & 700194454) the European Commission has granted marketing authorization for reslizumab for the treatment of asthma.
    • 24 Jun 2016 According to a Teva Pharmaceuticals media release, based on the data from this and other four trials (700194103, 700194191, 700212125 & 700194454) the EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for reslizumab for the treatment of severe eosinophilic asthma. The final decision by the European Commission is expected in the second half of 2016.
    • 28 Apr 2016 Time frame of the primary end point changed from only 16 weeks to Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top